EP2746280A1 - Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient - Google Patents
Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient Download PDFInfo
- Publication number
- EP2746280A1 EP2746280A1 EP12824562.8A EP12824562A EP2746280A1 EP 2746280 A1 EP2746280 A1 EP 2746280A1 EP 12824562 A EP12824562 A EP 12824562A EP 2746280 A1 EP2746280 A1 EP 2746280A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- quamoclit
- group
- complications
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 148
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000004480 active ingredient Substances 0.000 title claims abstract description 16
- 239000000126 substance Substances 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 206010022489 Insulin Resistance Diseases 0.000 claims description 11
- 239000012223 aqueous fraction Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 9
- 208000002177 Cataract Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 230000003178 anti-diabetic effect Effects 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 4
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 229960002632 acarbose Drugs 0.000 claims description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 4
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 229960004346 glimepiride Drugs 0.000 claims description 4
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010010719 Conjunctival haemorrhage Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000003790 Foot Ulcer Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 3
- 206010056997 Impaired fasting glucose Diseases 0.000 claims description 3
- 206010022941 Iridocyclitis Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 201000007737 Retinal degeneration Diseases 0.000 claims description 3
- 206010040943 Skin Ulcer Diseases 0.000 claims description 3
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims description 3
- 201000004612 anterior uveitis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 206010062198 microangiopathy Diseases 0.000 claims description 3
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 230000004258 retinal degeneration Effects 0.000 claims description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 2
- 150000004283 biguanides Chemical class 0.000 claims description 2
- 229950004994 meglitinide Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 229960000698 nateglinide Drugs 0.000 claims description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 2
- 229940096058 prandin Drugs 0.000 claims description 2
- 229960002354 repaglinide Drugs 0.000 claims description 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 abstract description 50
- 239000008280 blood Substances 0.000 abstract description 49
- 230000000694 effects Effects 0.000 abstract description 42
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 12
- 235000000346 sugar Nutrition 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 10
- 230000003914 insulin secretion Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 52
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 49
- 239000008103 glucose Substances 0.000 description 49
- 241000699666 Mus <mouse, genus> Species 0.000 description 48
- 102000004877 Insulin Human genes 0.000 description 26
- 108090001061 Insulin Proteins 0.000 description 26
- 229940125396 insulin Drugs 0.000 description 26
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 102000051325 Glucagon Human genes 0.000 description 14
- 108060003199 Glucagon Proteins 0.000 description 14
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 14
- 229960004666 glucagon Drugs 0.000 description 14
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 13
- 108091005995 glycated hemoglobin Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 108010076365 Adiponectin Proteins 0.000 description 10
- 102000011690 Adiponectin Human genes 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 210000000695 crystalline len Anatomy 0.000 description 8
- 230000036252 glycation Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- -1 liquid paraffin Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 208000002249 Diabetes Complications Diseases 0.000 description 6
- 206010012655 Diabetic complications Diseases 0.000 description 6
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 108010028144 alpha-Glucosidases Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010007749 Cataract diabetic Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000007025 diabetic cataract Diseases 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010024214 Lenticular opacities Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000006481 glucose medium Substances 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 108010004903 glycosylated serum albumin Proteins 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000007056 liver toxicity Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100001092 no hepatotoxicity Toxicity 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 2
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 240000001549 Ipomoea eriocarpa Species 0.000 description 2
- 235000005146 Ipomoea eriocarpa Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001437 anti-cataract Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- SHZGCJCMOBCMKK-FPRJBGLDSA-N beta-D-fucose Chemical compound C[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-FPRJBGLDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229940127208 glucose-lowering drug Drugs 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 0 C*CCCC(CCCC(*)CC1OC1*)OC1OC(C*(C(C(*)CC(C)OC2*C*C(C)C(C*)CC2)I=C)=C)C(*)C(*)C1OCC(CC1O)OC(C)N1OC(CC1C*)OC(CCC(COC2C)C(*)C2OC)C1O Chemical compound C*CCCC(CCCC(*)CC1OC1*)OC1OC(C*(C(C(*)CC(C)OC2*C*C(C)C(C*)CC2)I=C)=C)C(*)C(*)C1OCC(CC1O)OC(C)N1OC(CC1C*)OC(CCC(COC2C)C(*)C2OC)C1O 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 240000003978 Ipomoea coccinea Species 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003904 glomerular cell Anatomy 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000021262 pancreatic insulin-producing neuroendocrine tumor Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a novel compound isolated from Quamoclit sp. and a composition comprising thereof as an active ingredient, and more particularly to a novel compound isolated from Quamoclit sp. and a composition for preventing or treating diabetes and its complications comprising the compound as an active ingredient.
- Diabetes refers to a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion or action. When abnormally high blood glucose levels are continued for a long period time, various complications occur due to chronic metabolic disorders and the result chronic vascular injuries.
- NIDDM Non-insulin dependent diabetes
- NIDDM neurodeficiency erythematosus .
- dietary therapy and exercise therapy are first attempted, and if the therapeutic effects of such therapies are insufficient, drugs are used, and in many cases, insulin is used.
- Insulin is required for patients whose blood glucose levels are not regulated by dietary therapy and oral blood glucose lowering drugs.
- insulin is a protein, it is inactivated by hydrolysis in the stomach. For this reason, it cannot be administered orally and should be injected intravenously or subcutaneously.
- Oral blood glucose lowering drugs improve the sensitivity of insulin receptor of a cell and stimulate the pancreases to promote secretion of insulin, and thus they are used to regulate blood glucose levels in NIDDM patients.
- oral therapy for treatment of NIDDM can cause hypoglycemia, nausea, vomiting, diarrhea, eruption and the like. Particularly, it can cause serious adverse effects such as fatal lactic acidosis.
- oral blood glucose lowering agents when used for a long time, cause cardiovascular disorders or gastrointestinal and hepatic disorders. For this reason, the long-term use thereof is not recommended. Due to such shortcomings and adverse effects, among current therapeutic drugs, there are little or no drugs, which show satisfactory effects, have high safety without adverse effects and can be applied to all diabetic patients. Thus, there is an urgent need to develop a more efficient drug for treating diabetes, particularly NIDDM.
- Such complications include acute diseases, such as hypoglycemia, ketoacidosis, hyperosmolar nonketotic hyperglycemia, hyperglycemic coma, and diabetic ketoacidosis; and chronic diseases, such as diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, cardiovascular complications, and viral infections.
- Chronic diabetic nephropathy is the most important cause of hemodialysis and end-stage renal failure, and diabetic cataract causes blindness, and eventually leading to death.
- the mechanisms causing diabetes are generally described by nonenzymatic glycation of proteins, polyol pathways, and the like.
- the non-enzymatic glycation of protein is caused by condensation of amino acid group such as lysine residue of protein with reduced sugar without enzymatic action, that is, the Maillard reaction. As a result of the reaction, glycation end products are produced.
- the non-enzymatic glycation of protein includes two steps.
- an amino acid group such as lysine of protein
- aldehyde or ketone of reduced sugar are subjected to a nucleophilic addition reaction without enzymatic action to form a Schiff base, a product of the early stage, and the Schiff base is condensed with the adjacent ketoamine adduct to produce a reversible Amadori-type early glycation product.
- the second step as the high blood glucose level is kept, the reversible Amadori type early glycation product is rearranged without degradation and is cross-linked with a protein to form irreversible advanced glycation end products.
- the advanced glycation end products are irreversible products. Therefore, the advanced glycation end products are not degraded, even when the blood glucose level is returned to the normal level, but they are accumulated in tissue to abnormally change the structure and function of the tissue for the survival period of the protein, thus causing complications in the tissue ( Vinson, J.A. et al., J. Nutritinal Biochemistry, 7: 559, 1996 ; Smith, P. R. et al., Eur. J. Biochem., 210:729, 1992 ).
- glycated albumin which is one of the advanced glycation end products produced by the reaction of glucose with various proteins acts as the major cause of chronic diabetic nephropathy.
- the glycated albumin is more easily introduced into glomerular cells compared to normal albumin, and a high concentration of glucose stimulates mesangial cells to increase the synthesis of extracellular matrix.
- the excessively introduced glycated albumin and the increased extracellular matrix cause the fibrosis of glomeruli. By these mechanisms, the glomeruli are continuously damaged, so that extreme treatments such as hemodialysis and organ transplantation are necessarily required.
- proteins such as the basement membrane, plasma albumin, the crystalline lens protein, fibrin, collagen and the like are glycated.
- the advanced glycation end products abnormally change the structure and function of the tissue to cause chronic diabetic complications such as diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy and the like ( Yokozawa,T. et al., J. of Trad. Med.,18:107, 2001 ).
- it was found that inhibiting the formation of advanced glycation end products is very important in delaying the onset of diabetic complications or preventing or treating diabetic complications ( Brownlee, M. et al., N. Engl. Med., 318:1315, 1988 ).
- VEGF vascular endothelial growth factor
- VEGF in tumors or tissues suffering from diseases associated with these conditions expresses at an aberrantly high level, and has increased angiogenesis or vascular permeability.
- ARMD in particular is a clinically important angiogenic disease. This condition is characterized by choroidal neovascularization in one or both eyes in aging individuals, and is the major cause of blindness in industrialized countries.
- Anti-angiogenic agents used in various therapies can produce only a stoichiometric reduction in VEGF or VEGF receptor, and the agents are typically overwhelmed by the abnormally high production of VEGF by the diseased tissue ( Lopez et al., Invest. Opththalmol. Vis. Sci., 37:855, 1996 ).
- the present inventors have made extensive efforts to find a natural herbal substance for treating diabetes and its complications, which has less adverse effects.
- a novel compound isolated from Quamoclit sp. functions to improve diabetic indexes such as blood sugar, glycated hemoglobin, urine protein, etc. in diabetes mice, thereby completing the present invention.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes and its complications, which contains the novel compound as an active ingredient.
- the present invention provides a compound of chemical formula 1: wherein R1 and R2 are independently hydrogen, C 1-20 alkyl group, C 6-30 aryl group, C 1-20 allyl group, C 6-30 arylalkyl group or acyl group.
- the present invention also provides a method for preparing a compound of chemical formula 2, the method comprising the steps of: (a) extracting Quamoclit sp. with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, thereby preparing Quamoclit extract; (b) suspending the Quamoclit extract by adding water thereto, and fractionating with normal hexane, ethyl acetate and butanol, thereby obtaining water fraction; and (c) isolating and purifying the water fraction, thereby obtaining the compound of chemical formula 2;
- the present invention also provides a pharmaceutical composition for preventing or treating diabetes and its complications, which contains a compound of chemical formula 1; salt thereof; or extracts comprising a compound of chemical formula 1 or salt thereof, as an active ingredient.
- the present invention also provides a health functional food for preventing diabetes and its complications, which contains a compound of chemical formula 1; salt thereof; or extracts comprising a compound of chemical formula 1 or salt thereof, as an active ingredient.
- the present invention is directed to a compound of chemical formula 1: wherein R1 and R2 are independently hydrogen, C 1-20 alkyl group, C 6-30 aryl group, C 1-20 allyl group, C 6-30 arylalkyl group or acyl group.
- the R1 and R2 of chemical formula 1 may be independently hydrogen or C 1-20 alkyl group.
- the compound of chemical formula 1 may comprise a structure of chemical formula 2:
- the compound of chemical formula 1 may be derived from Quamoclit sp., and preferably derived from Quamoclit angulata.
- Quamoclit angulata that is used in the present invention is a annual vine plant belonging to the family Convolvulaceae of the order Tubiflorae. It is native to tropical Africa and is cultivated mainly for ornamental purposes. It is characterized in that the vines grow similar to a morning glory and are rolled up on the left side. The whole plant has a length of about 3 m.
- the leaves are alternate with long petioles and are heartes shaped. The tips of a leaf are acute and the both ends of the lower region in the leaf are pointed.
- the flower resemble the appearance of a morning glory and has 5 sepals, 5 stamens and 1 pistil.
- the fruit is capsular, ripens in September and has a sepal remaining thereon. This plant is similar to Quamoclit coccinea, but the leaf is not divided.
- the compound which contains a structure of chemical formula 2 according to the present invention is a novel compound isolated from Quamoclit sp., has an elemental chemical formula of C 49 H 88 O 24 , is a kind of resin glycoside having a structure of chemical formula 1, and sugar structure such as beta-D-fucopyranose and the like is linked thereto.
- the compound of chemical formula 2 is named as KRIBB-BH-P.
- the novel compound is bright yellow color powder.
- LC-MS result of the compound shows molecular ion m/z 1059.4, 916.4(1052.4-145), 786.9 (916.4-136), 514.8(786.9-136), 378.9(514.8-136), 232.9(378.9-146), and the result is consistent with the elemental chemical formula of C 49 H 88 O 24 . Additionally, NMR assignment is completed through 1D-NMR (H-NMR, C-NMR).
- a novel compound according to the present invention can be prepared using a known method.
- the compound can be extracted with a solvent selected from among water, an alcohol, an aqueous alcohol solution, an organic solvent, and mixtures thereof.
- the compound may be extracted using water or alcohol.
- the compound can be purified using activated carbon.
- the compound of chemical formula 2 can be prepared by the following method.
- the present invention is directed to a method for preparing a compound of chemical formula 2, the method comprising the steps of: (a) extracting Quamoclit sp. with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, thereby preparing Quamoclit extract; (b) suspending the Quamoclit extract by adding water thereto, and fractionating with normal hexane, ethyl acetate and butanol, thereby obtaining water fraction; and (c) isolating and purifying the water fraction, thereby obtaining the compound of chemical formula 2.
- step (a) preferably, Quamoclit is dried, and Quamoclit extract is primarily isolated and purified using carbon-packed column.
- the method for isolating and purifying in the step (c) can be, but not limited to, for example, chromatography.
- the compound of chemical formula 2 was prepared by the following manner. 51 g of crushed Quamoclit angulata was extracted with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, in an ultrasonic extractor at room temperature for 15 minutes at 2-hr intervals for 2-3 days or hot water extracted with a solvent of water at 50°C. The resulting extract was extracted under reduced pressure in a rotary vacuum evaporator at room temperature, and the concentrator was dried in a vacuum freeze dryer and then dissolved in water, thereby obtaining a Quamoclit angulata extract.
- a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof
- the obtained Quamoclit angulata extract was passed through an activated carbon-packed column to absorb the active components thereof onto the activated carbon. Then, the activated carbon-packed column was washed with distilled water to remove non-adsorbed components. Then, to the activated carbon-packed column from which the non-adsorbed components have been removed, an organic solvent such as 10-50% (v/v) ethanol was added while increasing the concentration continuously or stepwise, so that the active components of Quamoclit angulata adsorbed onto the activated carbon were purified by elution. Then, the Quamoclit angulata extract was collected.
- the Quamoclit angulata extract purified as described above was concentrated under reduced pressure in a rotary vacuum evaporator at room temperature, and the concentrated extract was freeze-dried in a vacuum, and then dissolved in water, thereby obtaining an aqueous solution of a Quamoclit angulata extract.
- aqueous solution of a Quamoclit angulata extract was suspended with distilled water, and then fractionated with n-hexane, ethyl acetate (EtOAc) and butanol (BuOH) in order, thereby obtaining n-hexane fractions, EtOAc fractions, BuOH fractions and water fractions, respectively.
- EtOAc ethyl acetate
- BuOH butanol
- the water fraction which showed the most excellent efficacy was divided into 10 fractions through column chromatography using silica gel as a stationary phase and Aetonitril-water mixture solvent (1:9 ⁇ 9:1 v/v) as a mobile phase, and Sephadex column chromatography (5.0X65 cm, MeOH) was performed of ACN20 [elution with Acertonitril-DW (2:8 v/v)], thereby purifying a novel compound.
- KRIBB-BH-P was injected into diabetic mice, it was demonstrated that there was no hepatotoxicity or disorder of liver function. Thereby it was demonstrated that the application of KRIBB-BH-P in vivo is safe.
- the present invention is directed to a pharmaceutical composition for preventing or treating diabetes and its complications or a health functional food for preventing diabetes and its complications, which contains a compound of chemical formula 1; salt thereof; or extracts comprising a compound of chemical formula 1 or salt thereof, as an active ingredient.
- the R1 and R2 of chemical formula 1 may be independently hydrogen or C 1-20 alkyl group. More preferably, the compound of chemical formula 1 may comprise a structure of chemical formula 2.
- the pharmaceutical composition and the health functional food can further comprises an extract obtained by plant-culturing or tissue-culturing.
- the novel compound of the present invention can prevent or treat not only diabetes, but also diabetic complications, but not limited to, which are selected from the group consisting of hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, impaired fasting glucose, impaired glucose tolerance, obesity, arteriosclerosis, microangiopathy, renal disease, heart disease, foot ulcer, arthritis, osteoporosis, and ophthalmologic disease induced by diabetes.
- diabetes is intended to include all types of diabetes, including type 1 diabetes, type 2 diabetes, adult diabetes occurring in young persons, latent autoimmune diabetes, and pancreatic diabetes, as well as diabetic complications, including not only the above examples but also glomerulosclerosis, impotence, diabetic neuropathy, premenstrual syndrome, restenosis, ulcerative colitis, coronary heart disease, high blood pressure, angina pectoris, myocardial infarction, stroke, disease of skin and connective tissue, metabolic acidosis, symptoms from poor glucose tolerance, etc.
- ocular diseases is intended to include, in addition to diabetic retinopathy, all ocular diseases caused by diabetes, including a cataract, macular degeneration, external ophthalmoplegia, iridocyclitis, neuritis, glaucoma, retinal degeneration, fundus hemorrhage, ametropia, subconjunctival hemorrhage, and vitreous haemorrhage.
- the pharmaceutical composition of the present invention contains a novel compound isolated from Quamoclit as an active ingredient, and may be provided as a pharmaceutical composition containing the novel compound alone or in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.
- the pharmaceutical composition of the present invention may also be used in combination with an agent for treating diabetes or its complications, known in the art. Namely, the pharmaceutical composition of the present invention may also be administrated with compounds having an effect on preventing or treating diabetes and its complications known in the art.
- the pharmaceutical composition of the present invention may further comprise an anti-diabetic compound, known in the art.
- the antidiabetic compound is selected from, but not limited to, the group consisting of nateglinide, repaglinide, glitazones, sulfonylureas, metformin, glimepiride, thiazolidinediones, biguanides, acarbose which is ⁇ -glucosidase inhibitor, and prandin of meglitinides.
- the administration manner of the pharmaceutical composition includes oral, intravenous, intramuscular, intracoronary, intrabone-marrow, intradural, intracardiac, dermal, subcutaneous, intraperitoneal, intranasal, enteral, local, sublingual and rectal administration.
- parenteral is intended to include subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrabursa, intrasternum, intradural, intrafocal and intracranial injection or implantation techniques.
- the pharmaceutical composition of the present invention can be a form of formulation for injection as a water or oil suspension for sterilized injection.
- the suspension can be prepared using an appropriate dispersing agent, a wetting agent (for example, Twin 80), or an suspending agent, by the known art in the field of the present invention.
- the formulation for injection may be a formulation for injection or a suspension (for example, 1,3-butandiol solution), in nontoxic and parenterally acceptable, a diluents or a solvent. There are mannitol, water, Ringer's solution, isotonic sodium chloride solution as an acceptable vehicle and solvent.
- sterilized non-volatile oil is commonly used as a solvent or a suspending medium.
- Any non-volatile oil which comprises synthetic mono- or di-glyceride and thus less irritation can be used.
- Natural oils which fatty acids such as oleic acid and its derivatives are acceptable for example, olive oil or castor oil), specifically those polyoxyethylated, are useful for a formulation for injection.
- the pharmaceutical composition of the present invention can be orally administrated as any form which is orally acceptable, but not limited to, including capsules, tablets, water suspension and solution.
- tablets for oral administration as commonly used carriers, lactose and corn starch are included.
- Lubricants such as magnesium stearate can be typically added.
- capsules for oral administration as useful diluents, lactose and corn starch are included.
- water suspension is orally administrated, an active ingredient is mixed with emulsifiers and suspending agents.
- a sweeting agent and/or a flavoring agent and/or a coloring agent can be added.
- the pharmaceutical composition of the present invention also can be administrated as a suppository form for rectal administration.
- the pharmaceutical composition can be prepared by mixing the compound of the present invention with nonirritating diluting agents which is solid at a room temperature and liquid at rectal temperature.
- the diluting agents include, but not limited to, cocoa butter, beeswax and polyethylene glycol.
- Oral administration of the pharmaceutical composition of the present invention is especially useful, when a targeted treatment is related to region or organ which is easy to access by local administration.
- the pharmaceutical composition need to be prepared as a proper ointment comprising an active ingredient suspended or dissolved in a carrier.
- the carrier for local administration of the compound of the present invention includes, but not limited to, mineral oil, liquid paraffin, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compound, oil wax and water.
- the pharmaceutical composition of the present invention can be prepared as a proper lotion or cream comprising an active ingredient suspended or dissolved in a carrier.
- the carrier for local administration of the compound of the present invention includes, but not limited to, mineral oil, sorbitan monostearate, polyxorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- the pharmaceutical composition of the present invention also can be locally applied by rectal suppository or enemata clyster through lower gasterointestine. Transdermal patch which is locally applied is included in the present invention.
- the pharmaceutical composition of the present invention can be administrated by intranasal aerosol or inhalation.
- composition can be prepared by the known art in the field of pharmacy, and can be prepared using a preserved agent such as benzyl alcohol, an absorption enhancer for increasing bioavailability, fluorocarbon and/or well-known solubilizing agent, or a dispersing agent, as a solution in salt water.
- a preserved agent such as benzyl alcohol, an absorption enhancer for increasing bioavailability, fluorocarbon and/or well-known solubilizing agent, or a dispersing agent, as a solution in salt water.
- the novel compound of the present invention is comprised at a therapeutically or preventively effective amount.
- the pharmaceutical composition of the present invention can be prepared as a pellet, a sugar-coated tablet, a capsule, a liquid formulation, gel, syrup, slurry or a suspension.
- the pharmaceutical composition of the present invention can be administrated into branchial pouch or digestive duct.
- the pharmaceutical composition of the present invention can be injected into a muscle cell or other cell in a muscle tissue, and can be injected into a visceral cell in an abdominal cavity.
- the pharmaceutical composition for oral administration can be prepared by mixing with solid diluting agent and active ingredients together, and can be prepared as a granulate form to prepare as a tablet or a sugar-coated tablet.
- the proper diluting agent includes sugar form such as lactose, sucrose, mannitol and sorbitol, gums including starch from corn, flour, rice, potato or other plant, cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose, arabic gum, tragacanth gum, protein filler including carbohydrate, gelatin, collagen.
- a disintegrating agent or a solvent of a salt form like cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginic acid can be added.
- the pharmaceutical composition can be prepared as an aqueous solution.
- physically appropriate buffer such as Hank's solution, Ringer's solution, or physically buffered salt water can be used.
- substrates which can increase viscosity of suspension like sodium carboxymethyl cellulose, sorbitol, or dextran, can be added.
- a suspension of an active ingredient can be prepared as an oily injection suspension.
- Proper lipophilic solvent or carrier includes fatty acid as sesame oil, and synthetic fatty acid ester as ethyl olate, triglyceride or liposome. Polycationic amino polymers can be used as a carrier. Randomly, proper stabilizers or drugs can be used to increase the solubility of the compound and prepare highly concentrated solution.
- the health functional food of the present invention can be prepared as a form of food for preventing or improving diabetes and its complications.
- the health functional food of the present invention is a food composition, and examples thereof include all types of food including functional food, nutritional supplement, health food, and food additives.
- the types of food mentioned above may be prepared in various forms by conventional methods known in the art.
- the novel compound isolated from Quamoclit of the present invention may be prepared in the form of tea, juice and drink, or it may be granulized, encapsulated or powdered.
- the functional food may be prepared by adding the novel compound isolated from Quamoclit of the present invention to beverages (including alcoholic beverage), fruits and processed foods thereof (e.g., canned fruit, bottled food, jam, marmalade, etc.), fishes, meats and processed foods thereof (e.g., ham, sausage, corn beef, etc.), bread and noodles (e.g., Japanese noodle, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, milk products (e.g., butter, cheese, etc.), edible plant oil and fat, margarine, vegetable proteins, a retort food, frozen food, various seasonings (e.g., soybean paste, soy sauce, sauces, etc.) and the like.
- beverages including alcoholic beverage
- fruits and processed foods thereof e.g., canned fruit, bottled food, jam, marmalade, etc.
- fishes, meats and processed foods thereof e.g.,
- the concentration was suspended in water and passed through column chromatography filled with activated carbon to adsorb effective component of the Quamoclit angulata and a column filled with activated carbon was washed with distilled water, thereby removing non-adsorbed component.
- An organic solvent such as 10 ⁇ 50%(v/v) ethanol, and the like, was supplied into the activated carbon-filled column from which the non-adsorbed component is removed while increasing concentration thereof in a continuous scheme or in stages to thereby elute, isolate and refine the effective component of the Quamoclit angulata adsorbed onto the activated carbon, thereby obtaining a Quamoclit angulata extract.
- the isolated and refined Quamoclit angulata extract was concentrated under reduced pressure, water was added to 5g of the concentrated Quamoclit angulata extract, thereby dissolving the Quamoclit angulata extract so as to have a concentration of 20mg/ml.
- the water extract was suspended in distilled water, followed by sequential solution fraction with normal hexane (n-hexane), ethyl acetate (EtOAc), and butanol (BuOH), thereby obtaining n-hexane fraction, EtOAc fraction, BuOH fraction, and water fraction, respectively.
- n-hexane normal hexane
- EtOAc ethyl acetate
- BuOH butanol
- VEGF Vascular Endothelial Growth Factor
- Example 1 The novel compound isolated in Example 1 above was a pale yellow powder, and had molecular ion m/z of 1059.4, 916.4(1052.4-145), 786.9 (916.4-136), 514.8(786.9-136), 378.9(514.8-136) and 232.9(378.9-146) detected by LC-MS ( FIG. 2 ), which was coincided with Molecular Formula (Elemental Formula) of C 49 H 88 O 24 .
- H-NMR Hydrogen nuclear magnetic resonance
- C-NMR Carbon nuclear magnetic resonance
- the compound has a structure with sugars linked to beta-D-fucopyranose as a kind of glucoside and is referred to as KRIBB-BH-P.
- ARPE 19 cell line which is human retinal pigment epithelium cell line was treated with the novel compound and expression of the VEGF protein inducting diabetic complications such as diabetic retinopathy, and the like was confirmed.
- fetal bovine serum FBS
- F12 medium and ARPE 19 cell line ATCC, USA
- FBS serum-free 10% fetal bovine serum-free was added to DMEM low glucose medium, followed by culturing for 24 hours, the culture fluid was changed into a culture fluid containing 30 mM glucose in the DMEM low glucose medium, and the novel compound KRIBB-BH-P was added thereto so that a final concentration thereof was 0.5 ⁇ g/ml, followed by culturing for 72 hours in order to confirm production of VEGF protein.
- a cell (- control group) in which the VEGF was not expressed by treatment with 5.5mM glucose was set as reference which is a control group and a degree of VEGF expression (+ control group) by treatment with 30mM glucose was confirmed, and comparison of VEGF expression inhibition activity of the Quamoclit angulata -derived compound was conducted.
- the 30mM glucose used in the present experiment is a concentration under conditions that optimally induce expression of VEGF at each experiment.
- the culture fluid of ARPE 19 cell cultured by the above-described method was obtained and an amount of the secreted VEGF was measured using VEGF ELISA kit (R&D, UK).
- Min 6 cell line which is a mouse pancreatic ⁇ cell tumor.
- FBS was added to HDMEM medium and Min 6(ATCC, USA) was cultured therein.
- the cells were smeared on a 96 well plate at a concentration of 1 x 10 4 cell/plate, 15% FBS serum-free was added to DMEM high glucose medium, followed by culturing for 72 hours, washing with PBS buffer solution, and then culturing in HBSS buffer solution for 2 hours, the culture fluid was changed into HBSS buffer solution having 25mM glucose added thereto, and the novel compound KRIBB-BH-P was added thereto so that a final concentration thereof was 0.5 ng/ml, followed by culturing for 2 hours in order to confirm whether or not the insulin expression was promoted.
- an amount of insulin expression in cell in which insulin expression was not induced by treatment with 5.5mM glucose was set as a reference point which is a control group, and a positive control group was prepared by adding amino-guanidine of 1 ⁇ M, acarbose of 1 ⁇ M, glimepiride of 1mM.
- a degree of insulin expression by treatment with 25mM glucose as a negative control group was confirmed, and comparison and analysis whether or not the Quamoclit angulata -derived novel compound promoted insulin expression were conducted.
- the culture fluid of Min 6 cell cultured by the above-described method was obtained and an amount of the secreted insulin was measured using Insulin ELISA kit (R&D, UK).
- Eyes of a mouse was extracted and put into an iodine solution to be disinfected and then only the lens was extracted.
- the extracted eyes were put into M199 medium and cultured in a cell incubator. 20mM xylose was added to the medium to induce lens opacity and the induced lens opacity was measured using CCD camera.
- mice and diabetic mice were treated with the Quamoclit angulata -derived novel compound and change in diabetic indexes including blood glucose, glycated hemoglobin, and urinary protein was confirmed.
- 6-week-old mice (Male C57BL/6J mouse, 20g, Central Lab. Animal Inc., Seoul) and 6-week-old diabetic mice (Male C57BL/Ks DB/DB mouse, 20g, Central Lab. Animal Inc., Seoul) were purchased and adopted under predetermined temperature (25°C) and humidity (50%) for 1 week and used in an experiment.
- a normal mouse control group, a diabetic mouse control group, a diabetic mouse group treated with drugs (glimepiride and acarbose), and a diabetic mouse group treated with Quamoclit angulata -derived novel compound were prepared, wherein each group had five mice, and each group treated with the combination administration of the Quamoclit angulata -derived novel compound was treated by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg and raised for 12 weeks.
- a change in blood glucose in mice of each group was measured every 2 weeks and urine was collected every 6 weeks to measure a urinary protein concentration, and mice was raised for 12 weeks and blood thereof was collected to measure glycated hemoglobin concentration.
- blood glucose was increased in the diabetic mouse control group as compared to the normal mouse control group; however, in the diabetic mouse group treated with combination administration of the drugs and each group treated with Quamoclit angulata -derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg, blood glucose was remarkably decreased.
- a 5-week-old mouse (Male C57BL/6J, 19g, Koatech, Pyeongtaek-si, Gyeonggi-do, Korea) was purchased and adopted under predetermined temperature (25°C) and humidity (50%) for 1 week and used in an experiment.
- a general diet group having a general feed as a food and a high-fat diet group having a high-fat feed as a feed were prepared, wherein each group had five mice, and raised for 2 weeks.
- mice were fasting for 16 hours, and the fasting blood glucose was measured, and then, the sample was orally administered at 1, 2, 4, 8, 16, and 24 hours before measuring the blood glucose, followed by oral administration of glucose 2 g/kg (body weight) and blood glucose thereof was measured every 30 minutes.
- the group at the time of 24 hours after the sample was orally administered showed the highest efficacy.
- glycated hemoglobin HbA1c
- a value of glycated hemoglobin in which sugar is combined with hemoglobin normally present in red blood cells is also increased when blood glucose is maintained at a high level. Since the glycated hemoglobin reflects an average blood glucose value for 2 to 4 months, it is useful for identify a degree of regulation of blood glucose in a long term.
- the glycated hemoglobin value was remarkably decreased in the diabetic mouse group treated with Quamoclit angulata -derived novel compound by oral administration at a concentration of 10mg/kg as compared to the normal mouse control group.
- Diabetic patients are common to have both of kidney and heart complication. Diabetes may damage kidney which filters and excretes our body's waste.
- creatinine test a concentration of creatinine in a blood may be measured and a function of kidney may be evaluated creatinine, which is a product obtained by dehydrating creatine produced after protein is used in muscle, is present in a blood with an extremely small amount. In the case in which a function of the kidney is deteriorated, creatinine may not be excreted.
- Urine and blood from diabetic model mouse of each group treated by oral administration for 12 weeks were collected, and creatinine was measured using ELISA kit (R&D, USA).
- Example 7 Liver Toxicity and Liver Function Tests on Diabetic Mouse Treated with Quamoclit angulata -Derived Novel Compound
- a 6-week-old mouse and a 6-week-old diabetic mouse which are the same as Example 5 above were adapted under predetermined temperature (25°C) and humidity (50%) for 1 week and used in a liver toxicity test.
- a normal mouse control group, a diabetic mouse control group, and each diabetic mouse group treated with Quamoclit angulata- derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg were prepared, wherein each group had five mice, and raised for 12 week. After raising the mice for 12 weeks, blood thereof was collected and a concentration of alanine transaminase was measured.
- the alanine transaminase which is a metabolic enzyme of amino acid, is used in a representative test for diagnosis and result observation. Maintenance in concentration of alanine transaminase indicates that there is no liver damage.
- a normal mouse control group, a diabetic mouse control group and each group treated with Quamoclit angulata -derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg were raised for 12 weeks and blood thereof were collected and a change in alanine transaminase measured using ELISA kit (Cusabio biotech, Japan).
- each diabetic mouse group treated with Quamoclit angulata -derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg had liver toxicity values which were similar to those of the normal mouse control group, and there was no liver toxicity in the groups treated with Quamoclit angulata -derived novel compound.
- bilirubin value was measured using ELISA kit (Cusabio biotech, Japan) using blood collected in Example above.
- ELISA kit Cusabio biotech, Japan
- bilirubin value of the group treated with Quamoclit angulata- derived novel compound was included in a normal range. Therefore, it may be appreciated that the composition of the present invention is safe composition not causing abnormal liver function.
- Example 8 Analysis of Insulin Resistance and ⁇ -cell Functionality of Diabetic Mouse Treated with Quamoclit angulata -Derived Novel Compound
- Insulin and blood glucose of the diabetic mouse group raised under conditions of Example 7 above were measured by the fasting blood test or glucose tolerance test and insulin sensitivity index thereof was calculated.
- Insulin resistance was evaluated using the insulin sensitivity index which is homeostasis assessment (HOMA)-IR and ⁇ -cell Functionality was evaluated by HOMA-beta.
- HOMA homeostasis assessment
- HOMA - IR Fasting insulin ⁇ IU / mL X Fasting glucose nmol / L ⁇ / 22.5
- HOMA - beta 20 X Fasting insulin U / mL / Fasting glucose mmol / L - 3.5
- Example 9 Adiponectin Concentration Analysis in Blood of Diabetic Mouse Treated With Quamoclit angulata -Derived Novel Compound
- adiponectin is secreted from fat cells and abundantly present in blood, is decreased in an obesity patient or type 2 diabetic.
- low hypoadiponectinemia is on the rise as a new risk factor of artherosclerotic disease, and a concentration of adiponectin in diabetic patients, in particular, patients accompanying macrovascular complications is decreased. That is, adiponectin has an anti-obesity action, an anti-diabetic action, anti-atherogenic action and an inhibition action of active oxygen generation.
- a concentration of adiponectin in the blood of the diabetic mouse group raised under conditions of Example 7 was measured using ELISA kit (R&D, USA).
- Example 10 Glucagon Concentration Analysis of Diabetic Mouse Treated with Quamoclit angulata -Derived Novel Compound
- a concentration of plasma glucagon in the diabetic control group was remarkably high as compared to the normal control group; however, the concentration of plasma glucagon in the diabetic control group treated with the novel compound according to the present invention was remarkably decreased to be lower than that of the group treated with the drugs.
- a ratio of insulin to glucagon in the diabetic control group was remarkably low as compared to the normal group.
- the concentration ratio of insulin to glucagon in the group treated with Quamoclit angulata -derived novel compound was remarkably increased as compared to the diabetic mouse control group, and thus, it could be appreciated that the Quamoclit angulata -derived novel compound may normalize abnormal concentration of insulin and glucagon caused by diabetes and inhibit deterioration of diabetes.
- Example 11 Dipeptidyl peptidase IV (DPP-IV) Inhibition Efficacy Analysis of Diabetic Mouse Treated with Quamoclit angulata -Derived Novel Compound
- GIP glucose dependent insulinotropic eptide
- GLP-1 glucagon like peptide
- DPP-4 dipeptidyl peptidase
- an activity of DPP IV was inhibited in the group treated with the Quamoclit angulata -derived novel compound.
- an increase in glycated hemoglobin and blood glucose may be inhibited and excellent effect for prevention or treatment of diabetes may be provided.
- Example 12 Alpha-Glucosidase Activity Inhibition Ratio Measurement of Diabetic Mouse Treated with Quamoclit angulata- Derived Novel Compound
- Alpha-glucosidase inhibitor inhibits a function of alpha-glucosidase distributed in intestinal mucosa to thereby inhibit postcibal blood glucose from being increased. That is, alpha-glucosidase has a role of decomposing polysaccharide into monosaccharide to promote absorption of monosaccharide into small intestine, wherein the novel compound inhibits such role and hinders absorption of monosaccharide to thereby delay digestion and absorption of carbohydrate in the ingested feed to decrease a rise in postcibal blood glucose and insulin in blood, thereby showing treatment effect of diabetes.
- the alpha-glucosidase inhibitor does not induce hyperinsulinemia or hypoglycemia but promotes secretion of glucagon-like peptide-1 promoting insulin secretion and inhibiting glucagon secretion at a small intestine.
- TNF-alpha Tumor Necrosis Factor-alpha
- Tumor necrosis factor-alpha is mainly expressed in a fat cell, an increase level of the cytokine is associated with obesity and insulin resistance.
- a fat tissue produces cytokines such as tumor necrosis factor-alpha (TNF- ⁇ ), resistin, interleukin-6(IL-6), wherein it was confirmed that the cytokines inhibit insulin action.
- cytokines such as tumor necrosis factor-alpha (TNF- ⁇ ), resistin, interleukin-6(IL-6), wherein it was confirmed that the cytokines inhibit insulin action.
- sympathetic nerve activity is increased, which increases fat decomposition and decreases blood flow of muscle (glucose transport) to thereby directly affect insulin action.
- Tumor necrosis factor-alpha increases blood glucose to induce diabetes and enters into blood vessel to prevent inflammation and to prevent secretion of adiponectin inhibiting built-up cholesterol, thereby hindering NF-kB signal transfer into vascular endothelial cell and inhibiting activity of phagocytosis by macrophage.
- TNF- ⁇ concentration of the diabetic mouse group raised under conditions of Example 7 above was measured based on the above-description.
- TNF- ⁇ concentration of the diabetic mouse group treated with quamoclit angulata-derived novel compound was decreased.
- Eye lens was isolated from eyeball extracted from the diabetic mouse group raised under conditions of Example 7 above and moved to a well plate and then a photograph thereof was taken by LAS 3000 image analysis system. Turbidity of the eye lens was measured by analyzing the photograph using LAS 300 image analysis program.
- the novel compound isolated from Quamoclit sp . has excellent effects on lowering blood sugar, promoting insulin secretion, inhibiting VEGF expression, and so on.
- the present invention not only functions to prevent or treat diabetes and its complications, but also functions to promote treatment effects when treated together with conventional diabetes medicines.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pediatric Medicine (AREA)
Abstract
Description
- The present invention relates to a novel compound isolated from Quamoclit sp. and a composition comprising thereof as an active ingredient, and more particularly to a novel compound isolated from Quamoclit sp. and a composition for preventing or treating diabetes and its complications comprising the compound as an active ingredient.
- Diabetes refers to a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion or action. When abnormally high blood glucose levels are continued for a long period time, various complications occur due to chronic metabolic disorders and the result chronic vascular injuries.
- Diabetes, a typical adult metabolic disease, is suffered by about 5% of the population in the world and causes a huge loss of lives and properties. Most diabetic patients take oral therapeutic agents, but a safe therapeutic agent has not yet been developed. Insulin resistance is known to be the most important cause of diabetes, but the exact mechanism of diabetes is still unknown, and it is known that diabetes is caused by genetic predisposition and environmental factors. Diabetes is the third leading cause of death in the world, and the number of diabetic patients in 2010 is estimated to be about 250 millions. In Korea, the number of diabetic patients is expected to increase continuously in the future. Non-insulin dependent diabetes (NIDDM) is the seventh leading cause of death in Korea and accounts for more than 90% of diabetic patients. It is called "adult diabetes", because it occurs mainly in persons who are over 40 years old. It is a metabolic disorder which is caused by the insufficient production or inappropriate use of insulin (DeFronzo RA et al., Diabetes Care, 15:318, 1992). Although the cause of onset of NIDDM is not yet clearly known, it is believes that NIDDM is caused by environmental factors, including westernized eating habits and life styles, as well as genetic factors such as obesity and lack of exercise. For treatment of NIDDM, dietary therapy and exercise therapy are first attempted, and if the therapeutic effects of such therapies are insufficient, drugs are used, and in many cases, insulin is used. Insulin is required for patients whose blood glucose levels are not regulated by dietary therapy and oral blood glucose lowering drugs. However, because insulin is a protein, it is inactivated by hydrolysis in the stomach. For this reason, it cannot be administered orally and should be injected intravenously or subcutaneously.
- Oral blood glucose lowering drugs improve the sensitivity of insulin receptor of a cell and stimulate the pancreases to promote secretion of insulin, and thus they are used to regulate blood glucose levels in NIDDM patients. However, oral therapy for treatment of NIDDM can cause hypoglycemia, nausea, vomiting, diarrhea, eruption and the like. Particularly, it can cause serious adverse effects such as fatal lactic acidosis. In addition, oral blood glucose lowering agents, when used for a long time, cause cardiovascular disorders or gastrointestinal and hepatic disorders. For this reason, the long-term use thereof is not recommended. Due to such shortcomings and adverse effects, among current therapeutic drugs, there are little or no drugs, which show satisfactory effects, have high safety without adverse effects and can be applied to all diabetic patients. Thus, there is an urgent need to develop a more efficient drug for treating diabetes, particularly NIDDM.
- About 10 years after the onset of diabetes, almost all the organs of the body are damaged, causing complications. Such complications include acute diseases, such as hypoglycemia, ketoacidosis, hyperosmolar nonketotic hyperglycemia, hyperglycemic coma, and diabetic ketoacidosis; and chronic diseases, such as diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, cardiovascular complications, and viral infections. Chronic diabetic nephropathy is the most important cause of hemodialysis and end-stage renal failure, and diabetic cataract causes blindness, and eventually leading to death.
- The mechanisms causing diabetes are generally described by nonenzymatic glycation of proteins, polyol pathways, and the like. The non-enzymatic glycation of protein is caused by condensation of amino acid group such as lysine residue of protein with reduced sugar without enzymatic action, that is, the Maillard reaction. As a result of the reaction, glycation end products are produced. The non-enzymatic glycation of protein includes two steps. In the first step, an amino acid group (such as lysine of protein) and aldehyde or ketone of reduced sugar are subjected to a nucleophilic addition reaction without enzymatic action to form a Schiff base, a product of the early stage, and the Schiff base is condensed with the adjacent ketoamine adduct to produce a reversible Amadori-type early glycation product. In the second step, as the high blood glucose level is kept, the reversible Amadori type early glycation product is rearranged without degradation and is cross-linked with a protein to form irreversible advanced glycation end products.
- Unlike the reversible Amadori type early glycation product, the advanced glycation end products are irreversible products. Therefore, the advanced glycation end products are not degraded, even when the blood glucose level is returned to the normal level, but they are accumulated in tissue to abnormally change the structure and function of the tissue for the survival period of the protein, thus causing complications in the tissue (Vinson, J.A. et al., J. Nutritinal Biochemistry, 7: 559, 1996; Smith, P. R. et al., Eur. J. Biochem., 210:729, 1992).
- For example, glycated albumin which is one of the advanced glycation end products produced by the reaction of glucose with various proteins acts as the major cause of chronic diabetic nephropathy. The glycated albumin is more easily introduced into glomerular cells compared to normal albumin, and a high concentration of glucose stimulates mesangial cells to increase the synthesis of extracellular matrix. The excessively introduced glycated albumin and the increased extracellular matrix cause the fibrosis of glomeruli. By these mechanisms, the glomeruli are continuously damaged, so that extreme treatments such as hemodialysis and organ transplantation are necessarily required. In addition, it was reported that, in the case of chronic diabetes, the collagen in arterial walls and the basement membrane protein in glomeruli bind to the advanced glycation end products and are accumulated in tissue (Brownlee, M. et al., Sciences, 232:1629:1986).
- Due to the non-enzymatic protein glycation as described above, proteins such as the basement membrane, plasma albumin, the crystalline lens protein, fibrin, collagen and the like are glycated. The advanced glycation end products abnormally change the structure and function of the tissue to cause chronic diabetic complications such as diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy and the like (Yokozawa,T. et al., J. of Trad. Med.,18:107, 2001). Thus, it was found that inhibiting the formation of advanced glycation end products is very important in delaying the onset of diabetic complications or preventing or treating diabetic complications (Brownlee, M. et al., N. Engl. Med., 318:1315, 1988).
- In addition, advanced glycation end products overexpress vascular endothelial growth factor (VEGF) mRNA and protein to cause non-proproliferative or proliferative diabetic retinopathy. Aberrant angiogenesis or the pathogenic growth of new blood vessels is involved in a number of conditions. Such conditions include diabetic retinopathy, psoriasis, exudative or wet age-related macular degeneration (ARMD), rheumatoid arthritis and other inflammatory diseases, and most cancers (Aiello et al., New Engl. J. Med, 331:1480, 1994; Peer et al. Lab. Invest., 72:638, 1995). The VEGF in tumors or tissues suffering from diseases associated with these conditions expresses at an aberrantly high level, and has increased angiogenesis or vascular permeability. ARMD in particular is a clinically important angiogenic disease. This condition is characterized by choroidal neovascularization in one or both eyes in aging individuals, and is the major cause of blindness in industrialized countries. Anti-angiogenic agents used in various therapies can produce only a stoichiometric reduction in VEGF or VEGF receptor, and the agents are typically overwhelmed by the abnormally high production of VEGF by the diseased tissue (Lopez et al., Invest. Opththalmol. Vis. Sci., 37:855, 1996).
- Accordingly, the present inventors have made extensive efforts to find a natural herbal substance for treating diabetes and its complications, which has less adverse effects. As a result, the present inventors have found that a novel compound isolated from Quamoclit sp. functions to improve diabetic indexes such as blood sugar, glycated hemoglobin, urine protein, etc. in diabetes mice, thereby completing the present invention.
- It is an object of the present invention to provide a novel compound, which has less adverse effects, isolated from a natural herbal substance for treating diabetes and its complications.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes and its complications, which contains the novel compound as an active ingredient.
-
- The present invention also provides a method for preparing a compound of
chemical formula 2, the method comprising the steps of: (a) extracting Quamoclit sp. with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, thereby preparing Quamoclit extract; (b) suspending the Quamoclit extract by adding water thereto, and fractionating with normal hexane, ethyl acetate and butanol, thereby obtaining water fraction; and (c) isolating and purifying the water fraction, thereby obtaining the compound ofchemical formula 2; - The present invention also provides a pharmaceutical composition for preventing or treating diabetes and its complications, which contains a compound of
chemical formula 1; salt thereof; or extracts comprising a compound ofchemical formula 1 or salt thereof, as an active ingredient. - The present invention also provides a health functional food for preventing diabetes and its complications, which contains a compound of
chemical formula 1; salt thereof; or extracts comprising a compound ofchemical formula 1 or salt thereof, as an active ingredient. -
-
FIG. 1 is HPLC spectrum of a novel compound isolated from Quamoclit angulata. -
FIG. 2 is LC-MS spectrum of a novel compound isolated from Quamoclit angulata. -
FIG. 3 is H-NMR spectrum of a novel compound isolated from Quamoclit angulata using D2O as a solvent. -
FIG. 4 is C-NMR spectrum of a novel compound isolated from Quamoclit angulata using D2O as a solvent. -
FIG. 5 is a graph showing the inhibition of VEGF protein production in human retinal epithelial cells by a novel compound isolated from Quamoclit angulata. -
FIG. 6 is a graph showing the stimulation of insulin protein production in mouse pancreatic beta-cells by a novel compound isolated from Quamoclit angulata. -
FIG. 7 shows the effect of a novel compound isolated from Quamoclit angulata on the reduction in the opacity of mouse lenses. -
FIG. 8 shows the effect of a novel compound isolated from Quamoclit angulata on the lowering of blood glucose levels in diabetic model animals. -
FIG. 9 shows the effect of a novel compound isolated from Quamoclit angulata on the reduction of blood sugar by glucose tolerance test. -
FIG. 10 shows the effect of a novel compound isolated from Quamoclit angulata on the inhibition of glycated hemoglobin in diabetic model animals. -
FIG. 11 shows the effect of a novel compound isolated from Quamoclit angulata on the normal excretion of creatine urine in diabetic model animals. -
FIG. 12 shows the effect of a novel compound isolated from Quamoclit angulata on hepatotoxicity in diabetic model animals. There is no hepatotoxicity in diabetic model animals. -
FIG. 13 shows the effect of a novel compound isolated from Quamoclit angulata on liver function in diabetic model animals. There is no disorder of liver function in diabetic model animals. -
FIG. 14 shows the effect of a novel compound isolated from Quamoclit angulata on the improvement of beta-function and the reduction of insulin glucose tolerance in diabetic model animals. -
FIG. 15 shows the effect of a novel compound isolated from Quamoclit angulata on increasing the expression of adiponectin in diabetic model animals. -
FIG. 16 shows the effect of a novel compound isolated from Quamoclit angulata on dcreasing the expression of glucagon in diabetic model animals. -
FIG. 17 shows the effect of a novel compound isolated from Quamoclit angulata on the inhibition of DPP-IV activity in diabetic model animals. -
FIG. 18 shows the effect of a novel compound isolated from Quamoclit angulata on the inhibition of α-glucosidase activity in diabetic model animals. -
FIG. 19 shows the effect of a novel compound isolated from Quamoclit angulata on dcreasing the expression of tumor necrosis factor alpha in diabetic model animals. -
FIG. 20 shows the effect of a novel compound isolated from Quamoclit angulata on anti-cataract in diabetic model animals. -
- Preferably, the R1 and R2 of
chemical formula 1 may be independently hydrogen or C1-20 alkyl group. -
- Also, the compound of
chemical formula 1 may be derived from Quamoclit sp., and preferably derived from Quamoclit angulata. Quamoclit angulata that is used in the present invention is a annual vine plant belonging to the family Convolvulaceae of the order Tubiflorae. It is native to tropical Africa and is cultivated mainly for ornamental purposes. It is characterized in that the vines grow similar to a morning glory and are rolled up on the left side. The whole plant has a length of about 3 m. The leaves are alternate with long petioles and are heartes shaped. The tips of a leaf are acute and the both ends of the lower region in the leaf are pointed. The flowers bloom between August and September and are yellowish red, and 3-5 flowers are suspended from each stalk. The flower resemble the appearance of a morning glory and has 5 sepals, 5 stamens and 1 pistil. The fruit is capsular, ripens in September and has a sepal remaining thereon. This plant is similar to Quamoclit coccinea, but the leaf is not divided. - The compound which contains a structure of
chemical formula 2 according to the present invention is a novel compound isolated from Quamoclit sp., has an elemental chemical formula of C49H88O24, is a kind of resin glycoside having a structure ofchemical formula 1, and sugar structure such as beta-D-fucopyranose and the like is linked thereto. - In the present invention, the compound of
chemical formula 2 is named as KRIBB-BH-P. The novel compound is bright yellow color powder. LC-MS result of the compound shows molecular ion m/z 1059.4, 916.4(1052.4-145), 786.9 (916.4-136), 514.8(786.9-136), 378.9(514.8-136), 232.9(378.9-146), and the result is consistent with the elemental chemical formula of C49H88O24. Additionally, NMR assignment is completed through 1D-NMR (H-NMR, C-NMR). - A novel compound according to the present invention can be prepared using a known method. For example, the compound can be extracted with a solvent selected from among water, an alcohol, an aqueous alcohol solution, an organic solvent, and mixtures thereof. Preferably, the compound may be extracted using water or alcohol. In addition, the compound can be purified using activated carbon.
- The compound of
chemical formula 2 can be prepared by the following method. In another aspect, the present invention is directed to a method for preparing a compound ofchemical formula 2, the method comprising the steps of: (a) extracting Quamoclit sp. with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, thereby preparing Quamoclit extract; (b) suspending the Quamoclit extract by adding water thereto, and fractionating with normal hexane, ethyl acetate and butanol, thereby obtaining water fraction; and (c) isolating and purifying the water fraction, thereby obtaining the compound ofchemical formula 2. - In the step (a), preferably, Quamoclit is dried, and Quamoclit extract is primarily isolated and purified using carbon-packed column. The method for isolating and purifying in the step (c) can be, but not limited to, for example, chromatography.
- In one aspect of the present invention, the compound of
chemical formula 2 was prepared by the following manner. 51 g of crushed Quamoclit angulata was extracted with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, in an ultrasonic extractor at room temperature for 15 minutes at 2-hr intervals for 2-3 days or hot water extracted with a solvent of water at 50°C. The resulting extract was extracted under reduced pressure in a rotary vacuum evaporator at room temperature, and the concentrator was dried in a vacuum freeze dryer and then dissolved in water, thereby obtaining a Quamoclit angulata extract. - The obtained Quamoclit angulata extract was passed through an activated carbon-packed column to absorb the active components thereof onto the activated carbon. Then, the activated carbon-packed column was washed with distilled water to remove non-adsorbed components. Then, to the activated carbon-packed column from which the non-adsorbed components have been removed, an organic solvent such as 10-50% (v/v) ethanol was added while increasing the concentration continuously or stepwise, so that the active components of Quamoclit angulata adsorbed onto the activated carbon were purified by elution. Then, the Quamoclit angulata extract was collected. The Quamoclit angulata extract purified as described above was concentrated under reduced pressure in a rotary vacuum evaporator at room temperature, and the concentrated extract was freeze-dried in a vacuum, and then dissolved in water, thereby obtaining an aqueous solution of a Quamoclit angulata extract.
- The aqueous solution of a Quamoclit angulata extract was suspended with distilled water, and then fractionated with n-hexane, ethyl acetate (EtOAc) and butanol (BuOH) in order, thereby obtaining n-hexane fractions, EtOAc fractions, BuOH fractions and water fractions, respectively.
- Using the solvent fractions, respectively, inhibition experiments of VEGF production were performed. The water fraction which showed the most excellent efficacy was divided into 10 fractions through column chromatography using silica gel as a stationary phase and Aetonitril-water mixture solvent (1:9→9:1 v/v) as a mobile phase, and Sephadex column chromatography (5.0X65 cm, MeOH) was performed of ACN20 [elution with Acertonitril-DW (2:8 v/v)], thereby purifying a novel compound.
- In one Example of the present invention, when the novel compound isolated from Quamoclit angulata, KRIBB-BH-P was injected into diabetic mice, it was demonstrated that diabetic indexes such as blood sugar, glycated hemoglobin, and the constitution of urine protein were improved.
- In addition, when the novel compound isolated from Quamoclit angulata, KRIBB-BH-P was injected into diabetic mice, it was demonstrated that there was no hepatotoxicity or disorder of liver function. Thereby it was demonstrated that the application of KRIBB-BH-P in vivo is safe.
- In another Example of the present invention, when the novel compound isolated from Quamoclit angulata, KRIBB-BH-P was injected into diabetic mice, it was demonstrated that adiponectin levels were increased, and thereby insulin resistance was improved. Also, it was demonstrated that glucagon levels became normal, which was abnormally increased in diabetic mice.
- In another aspect, the present invention is directed to a pharmaceutical composition for preventing or treating diabetes and its complications or a health functional food for preventing diabetes and its complications, which contains a compound of
chemical formula 1; salt thereof; or extracts comprising a compound ofchemical formula 1 or salt thereof, as an active ingredient. - In the present invention, preferably, the R1 and R2 of
chemical formula 1 may be independently hydrogen or C1-20 alkyl group. More preferably, the compound ofchemical formula 1 may comprise a structure ofchemical formula 2. - In the present invention, the pharmaceutical composition and the health functional food can further comprises an extract obtained by plant-culturing or tissue-culturing.
- The novel compound of the present invention can prevent or treat not only diabetes, but also diabetic complications, but not limited to, which are selected from the group consisting of hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, impaired fasting glucose, impaired glucose tolerance, obesity, arteriosclerosis, microangiopathy, renal disease, heart disease, foot ulcer, arthritis, osteoporosis, and ophthalmologic disease induced by diabetes.
- As used herein, the term "diabetes" is intended to include all types of diabetes, including
type 1 diabetes,type 2 diabetes, adult diabetes occurring in young persons, latent autoimmune diabetes, and pancreatic diabetes, as well as diabetic complications, including not only the above examples but also glomerulosclerosis, impotence, diabetic neuropathy, premenstrual syndrome, restenosis, ulcerative colitis, coronary heart disease, high blood pressure, angina pectoris, myocardial infarction, stroke, disease of skin and connective tissue, metabolic acidosis, symptoms from poor glucose tolerance, etc. - As used herein, the term "ocular diseases" is intended to include, in addition to diabetic retinopathy, all ocular diseases caused by diabetes, including a cataract, macular degeneration, external ophthalmoplegia, iridocyclitis, neuritis, glaucoma, retinal degeneration, fundus hemorrhage, ametropia, subconjunctival hemorrhage, and vitreous haemorrhage.
- The pharmaceutical composition of the present invention contains a novel compound isolated from Quamoclit as an active ingredient, and may be provided as a pharmaceutical composition containing the novel compound alone or in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.
- In addition, the pharmaceutical composition of the present invention may also be used in combination with an agent for treating diabetes or its complications, known in the art. Namely, the pharmaceutical composition of the present invention may also be administrated with compounds having an effect on preventing or treating diabetes and its complications known in the art.
- Therefore, the pharmaceutical composition of the present invention may further comprise an anti-diabetic compound, known in the art.
- The antidiabetic compound is selected from, but not limited to, the group consisting of nateglinide, repaglinide, glitazones, sulfonylureas, metformin, glimepiride, thiazolidinediones, biguanides, acarbose which is α-glucosidase inhibitor, and prandin of meglitinides.
- In the present invention, the administration manner of the pharmaceutical composition, but not limited to, includes oral, intravenous, intramuscular, intracoronary, intrabone-marrow, intradural, intracardiac, dermal, subcutaneous, intraperitoneal, intranasal, enteral, local, sublingual and rectal administration.
- Oral and parenteral administration is preferable. As used herein, the term "parenteral" is intended to include subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrabursa, intrasternum, intradural, intrafocal and intracranial injection or implantation techniques.
- The pharmaceutical composition of the present invention can be a form of formulation for injection as a water or oil suspension for sterilized injection. The suspension can be prepared using an appropriate dispersing agent, a wetting agent (for example, Twin 80), or an suspending agent, by the known art in the field of the present invention. The formulation for injection may be a formulation for injection or a suspension (for example, 1,3-butandiol solution), in nontoxic and parenterally acceptable, a diluents or a solvent. There are mannitol, water, Ringer's solution, isotonic sodium chloride solution as an acceptable vehicle and solvent. In addition, sterilized non-volatile oil is commonly used as a solvent or a suspending medium. Any non-volatile oil which comprises synthetic mono- or di-glyceride and thus less irritation can be used. Natural oils which fatty acids such as oleic acid and its derivatives are acceptable (for example, olive oil or castor oil), specifically those polyoxyethylated, are useful for a formulation for injection.
- The pharmaceutical composition of the present invention can be orally administrated as any form which is orally acceptable, but not limited to, including capsules, tablets, water suspension and solution. In case of tablets for oral administration, as commonly used carriers, lactose and corn starch are included. Lubricants such as magnesium stearate can be typically added. In case of capsules for oral administration, as useful diluents, lactose and corn starch are included. When water suspension is orally administrated, an active ingredient is mixed with emulsifiers and suspending agents. In case needed, a sweeting agent and/or a flavoring agent and/or a coloring agent can be added.
- The pharmaceutical composition of the present invention also can be administrated as a suppository form for rectal administration. The pharmaceutical composition can be prepared by mixing the compound of the present invention with nonirritating diluting agents which is solid at a room temperature and liquid at rectal temperature. The diluting agents include, but not limited to, cocoa butter, beeswax and polyethylene glycol.
- Oral administration of the pharmaceutical composition of the present invention is especially useful, when a targeted treatment is related to region or organ which is easy to access by local administration. In case of local administration to skin, the pharmaceutical composition need to be prepared as a proper ointment comprising an active ingredient suspended or dissolved in a carrier. The carrier for local administration of the compound of the present invention includes, but not limited to, mineral oil, liquid paraffin, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compound, oil wax and water. As another manner, the pharmaceutical composition of the present invention can be prepared as a proper lotion or cream comprising an active ingredient suspended or dissolved in a carrier. The carrier for local administration of the compound of the present invention includes, but not limited to, mineral oil, sorbitan monostearate,
polyxorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical composition of the present invention also can be locally applied by rectal suppository or enemata clyster through lower gasterointestine. Transdermal patch which is locally applied is included in the present invention. The pharmaceutical composition of the present invention can be administrated by intranasal aerosol or inhalation. The composition can be prepared by the known art in the field of pharmacy, and can be prepared using a preserved agent such as benzyl alcohol, an absorption enhancer for increasing bioavailability, fluorocarbon and/or well-known solubilizing agent, or a dispersing agent, as a solution in salt water. - In the pharmaceutical composition of the present invention, the novel compound of the present invention is comprised at a therapeutically or preventively effective amount.
- However, a specific amount for a specific patient may change according to several reasons including activity of used specific compound, age, weight, general health, sex, diet, administration time, administration manner, emission rate, drug mix and specific disease which will be prevented or treated. The pharmaceutical composition of the present invention can be prepared as a pellet, a sugar-coated tablet, a capsule, a liquid formulation, gel, syrup, slurry or a suspension.
- In case of administration of the pharmaceutical composition of the present invention into a subcutaneous cell from fish, the pharmaceutical composition can be administrated into branchial pouch or digestive duct. The pharmaceutical composition of the present invention can be injected into a muscle cell or other cell in a muscle tissue, and can be injected into a visceral cell in an abdominal cavity.
- Preferably, the pharmaceutical composition for oral administration can be prepared by mixing with solid diluting agent and active ingredients together, and can be prepared as a granulate form to prepare as a tablet or a sugar-coated tablet. The proper diluting agent includes sugar form such as lactose, sucrose, mannitol and sorbitol, gums including starch from corn, flour, rice, potato or other plant, cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose, arabic gum, tragacanth gum, protein filler including carbohydrate, gelatin, collagen. In case needed, a disintegrating agent or a solvent of a salt form like cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginic acid can be added.
- In case of parental administration, the pharmaceutical composition can be prepared as an aqueous solution. Preferably, physically appropriate buffer such as Hank's solution, Ringer's solution, or physically buffered salt water can be used. In case of an aqueous injection suspension, substrates which can increase viscosity of suspension like sodium carboxymethyl cellulose, sorbitol, or dextran, can be added. In addition, a suspension of an active ingredient can be prepared as an oily injection suspension. Proper lipophilic solvent or carrier includes fatty acid as sesame oil, and synthetic fatty acid ester as ethyl olate, triglyceride or liposome. Polycationic amino polymers can be used as a carrier. Randomly, proper stabilizers or drugs can be used to increase the solubility of the compound and prepare highly concentrated solution.
- The health functional food of the present invention can be prepared as a form of food for preventing or improving diabetes and its complications. The health functional food of the present invention is a food composition, and examples thereof include all types of food including functional food, nutritional supplement, health food, and food additives. The types of food mentioned above may be prepared in various forms by conventional methods known in the art. For example, for the health food, the novel compound isolated from Quamoclit of the present invention may be prepared in the form of tea, juice and drink, or it may be granulized, encapsulated or powdered. Also, the functional food may be prepared by adding the novel compound isolated from Quamoclit of the present invention to beverages (including alcoholic beverage), fruits and processed foods thereof (e.g., canned fruit, bottled food, jam, marmalade, etc.), fishes, meats and processed foods thereof (e.g., ham, sausage, corn beef, etc.), bread and noodles (e.g., Japanese noodle, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, milk products (e.g., butter, cheese, etc.), edible plant oil and fat, margarine, vegetable proteins, a retort food, frozen food, various seasonings (e.g., soybean paste, soy sauce, sauces, etc.) and the like.
- Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are illustrative purposes only and are not to be construed to limit the scope of the present invention.
- 51g of Quamoclit angulata collected in Seogwang-ri, Andeokmyeon, Seogwipo-si, Jeju-do, Korea was extracted by hot water extraction using water as a solvent at 50°C or by a sound wave extractor using a solvent selected from a group consisting of water, alcohol, an organic solvent, and a mixed solution thereof every 2 hours for 15 minutes over two to three days at room temperature. After the thus-obtained extract was concentrated by rotary vacuum evaporator under reduced pressure at room temperature, the extracted residue was dried by a vacuum freezer dryer and a dried extract of Quamoclit angulata was obtained. The concentration was suspended in water and passed through column chromatography filled with activated carbon to adsorb effective component of the Quamoclit angulata and a column filled with activated carbon was washed with distilled water, thereby removing non-adsorbed component. An organic solvent such as 10∼50%(v/v) ethanol, and the like, was supplied into the activated carbon-filled column from which the non-adsorbed component is removed while increasing concentration thereof in a continuous scheme or in stages to thereby elute, isolate and refine the effective component of the Quamoclit angulata adsorbed onto the activated carbon, thereby obtaining a Quamoclit angulata extract. The isolated and refined Quamoclit angulata extract was concentrated under reduced pressure, water was added to 5g of the concentrated Quamoclit angulata extract, thereby dissolving the Quamoclit angulata extract so as to have a concentration of 20mg/ml.
- The water extract was suspended in distilled water, followed by sequential solution fraction with normal hexane (n-hexane), ethyl acetate (EtOAc), and butanol (BuOH), thereby obtaining n-hexane fraction, EtOAc fraction, BuOH fraction, and water fraction, respectively.
- Each of the solvent fractions was subjected to Vascular Endothelial Growth Factor (VEGF) inhibition experiment, and among them, water fraction having the most excellent efficiency was divided into 10 fractions by column chromatography having C18 reverse phase silica gel as a stationary phase and acetonitrile-water mixed solvent (1:9→9:1 v/v) as a mobile phase. Among them, the fraction ACN 20 [MeOH-water (1:9 v/v) elution] was subjected to Sephadex column chromatography (5.0 x 65 cm, MeOH), thereby refining a novel compound (
FIG. 1 ). Conditions and result used in the above-described experiment was follows: - High Performance Liquid Chromatography (HPLC) Analysis (Shimadzu Model)
- Column: C18 Reverse Phase Column
- Mobile Solvent: 90% Methanol
- Flow Rate: 1ml/min
- Residence Time: 1.29 Minutes.
- The novel compound isolated in Example 1 above was a pale yellow powder, and had molecular ion m/z of 1059.4, 916.4(1052.4-145), 786.9 (916.4-136), 514.8(786.9-136), 378.9(514.8-136) and 232.9(378.9-146) detected by LC-MS (
FIG. 2 ), which was coincided with Molecular Formula (Elemental Formula) of C49H88O24. - A NMR assignment was clearly completed by 1D-NMR (H NMR, C NMR).
- Hydrogen nuclear magnetic resonance (H-NMR) result measured with water substituted with deuterium (D2O) as a solvent and tetramethylsilane (TMS) as a standard material was shown in
FIG. 3 . - Carbon nuclear magnetic resonance (C-NMR) result measured with water substituted with deuterium (D2O) as a solvent and tetramethylsilane (TMS) as a standard material was shown in
FIG. 4 . -
- The compound has a structure with sugars linked to beta-D-fucopyranose as a kind of glucoside and is referred to as KRIBB-BH-P.
- In order to confirm inhibition activity of VEGF of the novel compound isolated from the Quamoclit angulata prepared in Example 1 above, ARPE 19 cell line which is human retinal pigment epithelium cell line was treated with the novel compound and expression of the VEGF protein inducting diabetic complications such as diabetic retinopathy, and the like was confirmed.
- 10% fetal bovine serum (FBS) was added to DMEM; F12 medium and ARPE 19 cell line (ATCC, USA) was cultured therein. In order to induce expression of the VEGF protein from ARPE 19 cell line, the cells were smeared on 60Φ plate at a concentration of
1x 105 cell/plate, 10% FBS serum-free was added to DMEM low glucose medium, followed by culturing for 24 hours, the culture fluid was changed into a culture fluid containing 30 mM glucose in the DMEM low glucose medium, and the novel compound KRIBB-BH-P was added thereto so that a final concentration thereof was 0.5 µg/ml, followed by culturing for 72 hours in order to confirm production of VEGF protein. Here, a cell (- control group) in which the VEGF was not expressed by treatment with 5.5mM glucose was set as reference which is a control group and a degree of VEGF expression (+ control group) by treatment with 30mM glucose was confirmed, and comparison of VEGF expression inhibition activity of the Quamoclit angulata-derived compound was conducted. The 30mM glucose used in the present experiment is a concentration under conditions that optimally induce expression of VEGF at each experiment. - The culture fluid of ARPE 19 cell cultured by the above-described method was obtained and an amount of the secreted VEGF was measured using VEGF ELISA kit (R&D, UK).
- As a result, it was confirmed from
FIG. 5 that VEGF expression was decreased in the experimental group treated with KRIBB-BH-P was treated. - An insulin secretion acceleration activity of the novel compound KRIBB-BH-P isolated from Quamoclit angulata was confirmed in
Min 6 cell line which is a mouse pancreatic β cell tumor. - 15% FBS was added to HDMEM medium and Min 6(ATCC, USA) was cultured therein. In order to induce insulin expression from
Min 6 cell line, the cells were smeared on a 96 well plate at a concentration of 1 x 104 cell/plate, 15% FBS serum-free was added to DMEM high glucose medium, followed by culturing for 72 hours, washing with PBS buffer solution, and then culturing in HBSS buffer solution for 2 hours, the culture fluid was changed into HBSS buffer solution having 25mM glucose added thereto, and the novel compound KRIBB-BH-P was added thereto so that a final concentration thereof was 0.5 ng/ml, followed by culturing for 2 hours in order to confirm whether or not the insulin expression was promoted. Here, an amount of insulin expression in cell in which insulin expression was not induced by treatment with 5.5mM glucose was set as a reference point which is a control group, and a positive control group was prepared by adding amino-guanidine of 1µM, acarbose of 1µM, glimepiride of 1mM. A degree of insulin expression by treatment with 25mM glucose as a negative control group was confirmed, and comparison and analysis whether or not the Quamoclit angulata-derived novel compound promoted insulin expression were conducted. The culture fluid ofMin 6 cell cultured by the above-described method was obtained and an amount of the secreted insulin was measured using Insulin ELISA kit (R&D, UK). - As a result, it was confirmed from
FIG. 6 that insulin expression was increased in the pancreatic β cell line in which the novel compound KRIBB-BH-P was treated. - In the case of diabetic, a cataract is developed at an early stage, becomes rapidly worse and eyesight is rapidly deteriorated. Diabetes promotes opaque crystalline lens. Accordingly, diabetic cataract inhibition efficiency was examined by a lens culture experiment.
- Eyes of a mouse was extracted and put into an iodine solution to be disinfected and then only the lens was extracted. The extracted eyes were put into M199 medium and cultured in a cell incubator. 20mM xylose was added to the medium to induce lens opacity and the induced lens opacity was measured using CCD camera.
- As a result, it was confirmed from
FIG. 7 that the lens opacity was more inhibited in a group treated with the novel compound KRIBB-BH-P according to the present invention as compared to a positive control group treated with quercetin known as a material inhibiting cataract development. - Normal mice and diabetic mice were treated with the Quamoclit angulata-derived novel compound and change in diabetic indexes including blood glucose, glycated hemoglobin, and urinary protein was confirmed.
- 6-week-old mice (Male C57BL/6J mouse, 20g, Central Lab. Animal Inc., Seoul) and 6-week-old diabetic mice (Male C57BL/Ks DB/DB mouse, 20g, Central Lab. Animal Inc., Seoul) were purchased and adopted under predetermined temperature (25°C) and humidity (50%) for 1 week and used in an experiment.
- A normal mouse control group, a diabetic mouse control group, a diabetic mouse group treated with drugs (glimepiride and acarbose), and a diabetic mouse group treated with Quamoclit angulata-derived novel compound were prepared, wherein each group had five mice, and each group treated with the combination administration of the Quamoclit angulata-derived novel compound was treated by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg and raised for 12 weeks. A change in blood glucose in mice of each group was measured every 2 weeks and urine was collected every 6 weeks to measure a urinary protein concentration, and mice was raised for 12 weeks and blood thereof was collected to measure glycated hemoglobin concentration.
- As a result, in a change in blood glucose, as shown in
FIG. 8 , blood glucose was increased in the diabetic mouse control group as compared to the normal mouse control group; however, in the diabetic mouse group treated with combination administration of the drugs and each group treated with Quamoclit angulata-derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg, blood glucose was remarkably decreased. - In order to conduct an oral glucose tolerance test, a 5-week-old mouse (Male C57BL/6J, 19g, Koatech, Pyeongtaek-si, Gyeonggi-do, Korea) was purchased and adopted under predetermined temperature (25°C) and humidity (50%) for 1 week and used in an experiment. A general diet group having a general feed as a food and a high-fat diet group having a high-fat feed as a feed were prepared, wherein each group had five mice, and raised for 2 weeks. At the time of two weeks after feeding with high-fat diet, the experimental mice were fasting for 16 hours, and the fasting blood glucose was measured, and then, the sample was orally administered at 1, 2, 4, 8, 16, and 24 hours before measuring the blood glucose, followed by oral administration of glucose 2 g/kg (body weight) and blood glucose thereof was measured every 30 minutes.
- As a result, as shown in
FIG. 9 , the group at the time of 24 hours after the sample was orally administered showed the highest efficacy. - In order to decrease complications developed in patients receiving diabetes treatment, it is important to maintain blood glucose at an appropriate level. Since blood glucose measured at one time point may be changed by various factors, the most widely used test with a purpose of identifying a long-term change in regulation of blood glucose is glycated hemoglobin (HbA1c). A value of glycated hemoglobin in which sugar is combined with hemoglobin normally present in red blood cells is also increased when blood glucose is maintained at a high level. Since the glycated hemoglobin reflects an average blood glucose value for 2 to 4 months, it is useful for identify a degree of regulation of blood glucose in a long term.
- In order to confirm effects of the Quamoclit angulata-derived novel compound on the glycated hemoglobin, blood of the normal mouse control group, the diabetic mouse control group and each diabetic mouse group treated with Quamoclit angulata-derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg were collected every 6 weeks and glycated hemoglobin was measured using enzyme-linked immunosorbent assay (ELISA) kit (Cusabio biotech, Japan).
- As a result, as shown in
FIG. 10 , the glycated hemoglobin value was remarkably decreased in the diabetic mouse group treated with Quamoclit angulata-derived novel compound by oral administration at a concentration of 10mg/kg as compared to the normal mouse control group. - Diabetic patients are common to have both of kidney and heart complication. Diabetes may damage kidney which filters and excretes our body's waste. Through creatinine test, a concentration of creatinine in a blood may be measured and a function of kidney may be evaluated creatinine, which is a product obtained by dehydrating creatine produced after protein is used in muscle, is present in a blood with an extremely small amount. In the case in which a function of the kidney is deteriorated, creatinine may not be excreted. Urine and blood from diabetic model mouse of each group treated by oral administration for 12 weeks were collected, and creatinine was measured using ELISA kit (R&D, USA).
- As a result, as shown in
FIG. 11 , it was confirmed that each concentration of creatinine in the bloods collected from the group treated with combination administration and the group treated with Quamoclit angulata-derived novel compound was decreased; however, each concentration of creatinine in the urines was increased, which showed that creatinine was readily excreted. - A 6-week-old mouse and a 6-week-old diabetic mouse which are the same as Example 5 above were adapted under predetermined temperature (25°C) and humidity (50%) for 1 week and used in a liver toxicity test.
- A normal mouse control group, a diabetic mouse control group, and each diabetic mouse group treated with Quamoclit angulata-derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg were prepared, wherein each group had five mice, and raised for 12 week. After raising the mice for 12 weeks, blood thereof was collected and a concentration of alanine transaminase was measured.
- The alanine transaminase, which is a metabolic enzyme of amino acid, is used in a representative test for diagnosis and result observation. Maintenance in concentration of alanine transaminase indicates that there is no liver damage.
- In order to confirm effects of the Quamoclit angulata-derived novel compound on liver, a normal mouse control group, a diabetic mouse control group and each group treated with Quamoclit angulata-derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg were raised for 12 weeks and blood thereof were collected and a change in alanine transaminase measured using ELISA kit (Cusabio biotech, Japan).
- As a result, as shown in
FIG. 12 , it was confirmed that each diabetic mouse group treated with Quamoclit angulata-derived novel compound by oral administration at each concentration of 0.1 mg/kg, 1mg/kg and 10mg/kg had liver toxicity values which were similar to those of the normal mouse control group, and there was no liver toxicity in the groups treated with Quamoclit angulata-derived novel compound. - In order to confirm whether or not liver function was normal in the group treated with Quamoclit angulata-derived novel compound, bilirubin value was measured using ELISA kit (Cusabio biotech, Japan) using blood collected in Example above. As a result of Bilirubin analysis, as shown in
FIG. 13 , bilirubin value of the group treated with Quamoclit angulata-derived novel compound was included in a normal range. Therefore, it may be appreciated that the composition of the present invention is safe composition not causing abnormal liver function. - Insulin and blood glucose of the diabetic mouse group raised under conditions of Example 7 above were measured by the fasting blood test or glucose tolerance test and insulin sensitivity index thereof was calculated.
- Insulin resistance was evaluated using the insulin sensitivity index which is homeostasis assessment (HOMA)-IR and β-cell Functionality was evaluated by HOMA-beta.
-
- It has consistently proven that adiponectin is secreted from fat cells and abundantly present in blood, is decreased in an obesity patient or
type 2 diabetic. In addition, low hypoadiponectinemia is on the rise as a new risk factor of artherosclerotic disease, and a concentration of adiponectin in diabetic patients, in particular, patients accompanying macrovascular complications is decreased. That is, adiponectin has an anti-obesity action, an anti-diabetic action, anti-atherogenic action and an inhibition action of active oxygen generation. A concentration of adiponectin in the blood of the diabetic mouse group raised under conditions of Example 7 was measured using ELISA kit (R&D, USA). - As a result, as shown in
FIG. 15 , it was confirmed that expression of adiponectin, which is a value showing an improvement of insulin resistance, was decreased in the diabetic mouse control group; however, in the other groups, in particular, the experimental group treated with Quamoclit angulata-derived novel compound, expression of adiponectin was increased. - As hormones playing a key role in maintaining an appropriate blood glucose value, there are glucagon increasing glucose as well as insulin removing glucose.
- In
type 2 diabetic patients, blood glucose is increased, insulin secretion by glucose intake is delayed, and glucagon is increased. It is generally known that decrease in a ratio of insulin to plasma glucagon is associated with deterioration of diabetes. Therefore, a concentration of glucagon of the diabetic mouse group raised under conditions of Example 7 above was confirmed. - As a result, as shown in
FIG. 16 , a concentration of plasma glucagon in the diabetic control group was remarkably high as compared to the normal control group; however, the concentration of plasma glucagon in the diabetic control group treated with the novel compound according to the present invention was remarkably decreased to be lower than that of the group treated with the drugs. A ratio of insulin to glucagon in the diabetic control group was remarkably low as compared to the normal group. Therefore, due to administration of Quamoclit angulata-derived novel compound, the concentration ratio of insulin to glucagon in the group treated with Quamoclit angulata-derived novel compound was remarkably increased as compared to the diabetic mouse control group, and thus, it could be appreciated that the Quamoclit angulata-derived novel compound may normalize abnormal concentration of insulin and glucagon caused by diabetes and inhibit deterioration of diabetes. - There are two kinds of incretin such as glucose dependent insulinotropic eptide (GIP) and glucagon like peptide (GLP-1), and when glucose is increased in small intestine, two hormones are both secreted from endocrine cell in an epithelial cell layer of small intestine to thereby stimulate β-cell of the pancreas, promote insulin secretion, and inhibit glucagon secretion in α-cell.
- Therefore, incretin drops blood glucose dependent on concentration of orally ingested glucose and low blood glucose is hardly induced. Both of GIP and GLP-1 are rapidly decomposed by dipeptidyl peptidase (DPP)-4 which is a series of serine protease. DPP-4 inhibition efficacy of the diabetic mouse group raised under conditions of Example 7 above was confirmed based on the above description.
- As a result, as shown in
FIG. 17 , it could be appreciated that an activity of DPP IV was inhibited in the group treated with the Quamoclit angulata-derived novel compound. Through inhibition in the activity of DPP-IV spotlighted as a target of novel treatment against diabetes, an increase in glycated hemoglobin and blood glucose may be inhibited and excellent effect for prevention or treatment of diabetes may be provided. - Alpha-glucosidase inhibitor inhibits a function of alpha-glucosidase distributed in intestinal mucosa to thereby inhibit postcibal blood glucose from being increased. That is, alpha-glucosidase has a role of decomposing polysaccharide into monosaccharide to promote absorption of monosaccharide into small intestine, wherein the novel compound inhibits such role and hinders absorption of monosaccharide to thereby delay digestion and absorption of carbohydrate in the ingested feed to decrease a rise in postcibal blood glucose and insulin in blood, thereby showing treatment effect of diabetes. The alpha-glucosidase inhibitor does not induce hyperinsulinemia or hypoglycemia but promotes secretion of glucagon-like peptide-1 promoting insulin secretion and inhibiting glucagon secretion at a small intestine.
- Activity of alpha-glucosidase of the diabetic mouse group raised under conditions of Example 7 above was measured based on the above-description.
- As a result, as shown in
FIG. 18 , it could be appreciated that activity of alpha-glucosidase of the group treated with the novel compound of the present invention was inhibited. - Tumor necrosis factor-alpha (TNF-α) is mainly expressed in a fat cell, an increase level of the cytokine is associated with obesity and insulin resistance. A fat tissue produces cytokines such as tumor necrosis factor-alpha (TNF-α), resistin, interleukin-6(IL-6), wherein it was confirmed that the cytokines inhibit insulin action. In an obese person, sympathetic nerve activity is increased, which increases fat decomposition and decreases blood flow of muscle (glucose transport) to thereby directly affect insulin action. Tumor necrosis factor-alpha (TNF-α) increases blood glucose to induce diabetes and enters into blood vessel to prevent inflammation and to prevent secretion of adiponectin inhibiting built-up cholesterol, thereby hindering NF-kB signal transfer into vascular endothelial cell and inhibiting activity of phagocytosis by macrophage.
- TNF-α concentration of the diabetic mouse group raised under conditions of Example 7 above was measured based on the above-description.
- As a result, as shown in
FIG. 19 , it could be appreciated that TNF-α concentration of the diabetic mouse group treated with quamoclit angulata-derived novel compound was decreased. - Eye lens was isolated from eyeball extracted from the diabetic mouse group raised under conditions of Example 7 above and moved to a well plate and then a photograph thereof was taken by
LAS 3000 image analysis system. Turbidity of the eye lens was measured by analyzing thephotograph using LAS 300 image analysis program. - As a result, as shown in
FIG. 20 , it could be appreciated that turbidity in the group treated with Quamoclit angulata-derived novel compound was decreased. Although specific embodiments of the present invention are described in detail, it will be apparent to those skilled in the art that the specific description is merely desirable exemplary embodiment and should not be construed as limiting the scope of the present invention. Therefore, the substantial scope of the present invention will be defined by the accompanying claims and their equivalents. - As described above, the novel compound isolated from Quamoclit sp. according to the present invention has excellent effects on lowering blood sugar, promoting insulin secretion, inhibiting VEGF expression, and so on. Thus, the present invention not only functions to prevent or treat diabetes and its complications, but also functions to promote treatment effects when treated together with conventional diabetes medicines.
Claims (20)
- The compound of claim 1, wherein the R1 and R2 are independently hydrogen or C1-20 alkyl group.
- The compound of claim 1, wherein the compound is derived from Quamoclit sp.
- The compound of claim 4, wherein the Quamoclit sp. is Quamoclit angulata.
- A method for preparing a compound of chemical formula 2, the method comprising the steps of:(a) extracting Quamoclit sp. with a solvent selected from the group consisting of water, alcohol, an organic solvent, and mixtures thereof, thereby preparing Quamoclit extract;(b) suspending the Quamoclit extract by adding water thereto, and fractionating with normal hexane, ethyl acetate and butanol, thereby obtaining water fraction; and
- The method of claim 6, wherein the Quamoclit sp. is Quamoclit angulata.
- A pharmaceutical composition for preventing or treating diabetes and its complications, which contains a compound of chemical formula 1; salt thereof; or extract comprising a compound of chemical formula 1 or salt thereof, as an active ingredient:
- The pharmaceutical composition for preventing or treating diabetes and its complications of claim 8, wherein the R1 and R2 are independently hydrogen or C1-20 alkyl group.
- The pharmaceutical composition for preventing or treating diabetes and its complications of claim 8, wherein the pharmaceutical composition further comprises an extract obtained by plant-culturing or tissue-culturing of Quamoclit and a compound obtained from the extract.
- The pharmaceutical composition for preventing or treating diabetes and its complications of claim 8, wherein the complications are selected from the group consisting of hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, impaired fasting glucose, impaired glucose tolerance, obesity, arteriosclerosis, microangiopathy, renal disease, heart disease, foot ulcer, arthritis, osteoporosis, and ophthalmologic disease induced by diabetes.
- The pharmaceutical composition for preventing or treating diabetes and its complications of claim 12, wherein the ophthalmologic disease induced by diabetes is selected from the group consisting of diabetic retinopathy, cataract, macular degeneration, external ophthalmoplegia, iridocyclitis, optic neuritis, glaucoma, retinal degeneration, fundus hemorrhage, anomalies of refraction, subconjunctival hemorrhage, and vitreous hemorrhage.
- The pharmaceutical composition for preventing or treating diabetes and its complications of claim 8, wherein the pharmaceutical composition further comprises an antidiabetic compound.
- The pharmaceutical composition for preventing or treating diabetes and its complications of claim 14, wherein the antidiabetic compound is selected from the group consisting of nateglinide, repaglinide, glitazones, sulfonylureas, metformin, glimepiride, thiazolidinediones, biguanides, acarbose which is α-glucosidase inhibitor, and prandin of meglitinides.
- A health functional food for preventing diabetes and its complications, which contains a compound of chemical formula 1; salt thereof; or extract comprising a compound of formula 1 or salt thereof, as an active ingredient:
- The health functional food for preventing diabetes and its complications of claim 16, wherein the complications are selected from the group consisting of hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, impaired fasting glucose, impaired glucose tolerance, obesity, arteriosclerosis, microangiopathy, renal disease, heart disease, foot ulcer, arthritis, osteoporosis, and ophthalmologic disease induced by diabetes.
- The health functional food for preventing diabetes and its complications of claim 18, wherein the ophthalmologic disease induced by diabetes is selected from the group consisting of diabetic retinopathy, cataract, macular degeneration, external ophthalmoplegia, iridocyclitis, optic neuritis, glaucoma, retinal degeneration, fundus hemorrhage, anomalies of refraction, subconjunctival hemorrhage, and vitreous hemorrhage.
- The health functional food for preventing diabetes and its complications of claim 16, wherein the health functional food further comprises an extract obtained by plant-culturing or tissue-culturing of Quamoclit and a compound obtained from the extract.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110082445 | 2011-08-18 | ||
KR1020120064524A KR101550390B1 (en) | 2011-08-18 | 2012-06-15 | Novel Compound Isolated from Quamoclit and Composition for Preventing or Treating Diabetes Containing thereof |
PCT/KR2012/005129 WO2013024968A1 (en) | 2011-08-18 | 2012-06-28 | Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2746280A1 true EP2746280A1 (en) | 2014-06-25 |
EP2746280A4 EP2746280A4 (en) | 2015-01-14 |
EP2746280B1 EP2746280B1 (en) | 2016-05-25 |
Family
ID=47898461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12824562.8A Not-in-force EP2746280B1 (en) | 2011-08-18 | 2012-06-28 | Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient |
Country Status (9)
Country | Link |
---|---|
US (1) | US9487596B2 (en) |
EP (1) | EP2746280B1 (en) |
JP (1) | JP5973571B2 (en) |
KR (1) | KR101550390B1 (en) |
AU (1) | AU2012295728A1 (en) |
BR (1) | BR112014003759A2 (en) |
CA (1) | CA2845496A1 (en) |
MX (1) | MX2014001855A (en) |
WO (1) | WO2013024968A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2913491A1 (en) * | 2013-05-24 | 2014-11-27 | Korea Research Institute Of Bioscience | Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011102690A2 (en) * | 2010-02-19 | 2011-08-25 | 한국생명공학연구원 | Pharmaceutical composition for treating diabetes containing quamoclit angulata extracts |
WO2013025074A2 (en) * | 2011-08-17 | 2013-02-21 | 한국생명공학연구원 | Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract |
WO2013025073A2 (en) * | 2011-08-17 | 2013-02-21 | 한국생명공학연구원 | Composition for preventing or treating diabetes complications containing quamoclit pennata extract |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3830960B1 (en) * | 2005-08-12 | 2006-10-11 | 建仁 河乃 | Hair growth substance |
KR100988510B1 (en) * | 2005-10-17 | 2010-10-20 | 이행우 | Composition for Prevention of Type 2 Diabetes and its Complications and Health Supplement Foods containing The same |
-
2012
- 2012-06-15 KR KR1020120064524A patent/KR101550390B1/en active IP Right Grant
- 2012-06-28 MX MX2014001855A patent/MX2014001855A/en not_active Application Discontinuation
- 2012-06-28 US US14/239,136 patent/US9487596B2/en active Active
- 2012-06-28 AU AU2012295728A patent/AU2012295728A1/en not_active Abandoned
- 2012-06-28 CA CA2845496A patent/CA2845496A1/en not_active Abandoned
- 2012-06-28 WO PCT/KR2012/005129 patent/WO2013024968A1/en active Application Filing
- 2012-06-28 JP JP2014525914A patent/JP5973571B2/en active Active
- 2012-06-28 EP EP12824562.8A patent/EP2746280B1/en not_active Not-in-force
- 2012-06-28 BR BR112014003759-0A patent/BR112014003759A2/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011102690A2 (en) * | 2010-02-19 | 2011-08-25 | 한국생명공학연구원 | Pharmaceutical composition for treating diabetes containing quamoclit angulata extracts |
WO2013025074A2 (en) * | 2011-08-17 | 2013-02-21 | 한국생명공학연구원 | Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract |
WO2013025073A2 (en) * | 2011-08-17 | 2013-02-21 | 한국생명공학연구원 | Composition for preventing or treating diabetes complications containing quamoclit pennata extract |
Non-Patent Citations (1)
Title |
---|
See also references of WO2013024968A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR112014003759A2 (en) | 2017-06-13 |
EP2746280B1 (en) | 2016-05-25 |
CA2845496A1 (en) | 2013-02-21 |
EP2746280A4 (en) | 2015-01-14 |
JP2014524494A (en) | 2014-09-22 |
JP5973571B2 (en) | 2016-08-23 |
US20140179622A1 (en) | 2014-06-26 |
WO2013024968A1 (en) | 2013-02-21 |
KR20130020544A (en) | 2013-02-27 |
KR101550390B1 (en) | 2015-09-08 |
US9487596B2 (en) | 2016-11-08 |
MX2014001855A (en) | 2015-04-16 |
CN104125958A (en) | 2014-10-29 |
AU2012295728A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011216647B2 (en) | Pharmaceutical composition for treating diabetes containing Quamoclit angulata extracts | |
WO2013025073A2 (en) | Composition for preventing or treating diabetes complications containing quamoclit pennata extract | |
US20160130293A1 (en) | Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes | |
EP2746280B1 (en) | Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient | |
KR100891881B1 (en) | Composition for preventing and treating hyperlipidemia and vascular disease due to highly activated MMP comprising 3,4,5-trihydroxybenzaldehyde as an active ingredient | |
KR20220090474A (en) | Pharmaceutical composition for preventing or treating of fatty liver disease | |
KR102607239B1 (en) | Composition comprising as an active ingredient a sweet potato extract | |
KR101963439B1 (en) | Composition for prevention or treatment of metabolic disease containing arazyme as an active ingredient | |
KR100824365B1 (en) | Composition comprising the extracts, fractions and the isolated compounds of phyllostachys nigra munro for prevention or treatment of diabetic complications | |
CN104125958B (en) | Belong to, from cypress vine, the compound separated and comprise the compositions for preventing or treat diabetes of this compound as effective ingredient | |
KR102474858B1 (en) | Composition for anti-diabetes comprising a mixture of grains | |
US20150246088A1 (en) | Pharmaceutical composition for treating diabetes containing quamoclit angulata extract | |
KR102069971B1 (en) | Pharmaceutical composition for preventing or treating vascular diseases comprising securinine | |
JP6622867B2 (en) | Hexadecafloretol, a novel compound isolated from Ishige and uses thereof | |
US20220257708A1 (en) | Composition for preventing, treating or alleviating diabetes, comprising lgi3-derived peptide as an active ingredient | |
KR101043633B1 (en) | A composition comprising peptide for treatment or prevention of diabetes mellitus | |
KR20200119939A (en) | Pharmaceutical composition and health functional food comprising extract of mycelium from Ceriporia lacerata | |
KR20130099467A (en) | Food composition for preventing or improving diabetes contaning extract of lespedeza daurica | |
KR20130099476A (en) | Food composition for preventing or improving diabetes contaning extract of lespedeza maximowiczii | |
KR20140062681A (en) | Compositions and functional food for prevention or treatment of diabetic complications comprising using extract of paulownia coreana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140217 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20141211 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 407/12 20060101ALI20141205BHEP Ipc: C07D 407/14 20060101AFI20141205BHEP Ipc: A61K 36/39 20060101ALI20141205BHEP Ipc: A61K 31/351 20060101ALI20141205BHEP Ipc: A61P 3/10 20060101ALI20141205BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20151118 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NANOBIOTECH CO., LTD. |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Ref country code: AT Ref legal event code: REF Ref document number: 802227 Country of ref document: AT Kind code of ref document: T Effective date: 20160615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012019057 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160825 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 802227 Country of ref document: AT Kind code of ref document: T Effective date: 20160525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160926 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012019057 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20160825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 |
|
26N | No opposition filed |
Effective date: 20170228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160628 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160825 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20170628 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20170629 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160628 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160630 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160525 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012019057 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190101 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180630 |